Literature DB >> 11319229

Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer.

K S Choi1, S L Fitzpatrick, N R Filipenko, D K Fogg, G Kassam, A M Magliocco, D M Waisman.   

Abstract

In a previous report we showed that plasmin-dependent lysis of a fibrin polymer, produced from purified components, was totally blocked if annexin II heterotetramer (AIIt) was present during fibrin polymer formation. Here, we show that AIIt inhibits fibrin clot lysis by stimulation of plasmin autodegradation, which results in a loss of plasmin activity. Furthermore, the C-terminal lysine residues of its p11 subunit play an essential role in the inhibition of fibrin clot lysis by AIIt. We also found that AIIt binds to fibrin with a K(d) of 436 nm and a stoichiometry of about 0.28 mol of AIIt/mol of fibrin monomer. The binding of AIIt to fibrin was not dependent on the C-terminal lysines of the p11 subunit. Furthermore, in the presence of plasminogen, the binding of AIIt to fibrin was increased to about 1.3 mol of AIIt/mol of fibrin monomer, suggesting that AIIt and plasminogen do not compete for identical sites on fibrin. Immunohistochemical identification of p36 and p11 subunits of AIIt in a pathological clot provides important evidence for its role as a physiological fibrinolytic regulator. These results suggest that AIIt may play a key role in the regulation of plasmin activity on the fibrin clot surface.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319229     DOI: 10.1074/jbc.M101426200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  The Kunitz-like modulatory protein haemangin is vital for hard tick blood-feeding success.

Authors:  M Khyrul Islam; Naotoshi Tsuji; Takeharu Miyoshi; M Abdul Alim; Xiaohong Huang; Takeshi Hatta; Kozo Fujisaki
Journal:  PLoS Pathog       Date:  2009-07-10       Impact factor: 6.823

2.  Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity.

Authors:  Haibin Dai; Zhanyang Yu; Xiang Fan; Ning Liu; Min Yan; Zhong Chen; Eng H Lo; Katherine A Hajjar; Xiaoying Wang
Journal:  Thromb Haemost       Date:  2013-03-21       Impact factor: 5.249

3.  Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen.

Authors:  Xiaohui Zhang; Huarong Zhou; Guanxin Shen; Zhongping Liu; Yu Hu; Wenning Wei; Shanjun Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

4.  tPA receptors and the fibrinolytic response in multiple sclerosis lesions.

Authors:  Djordje Gveric; Blanca M Herrera; M Louise Cuzner
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Annexin A2: the importance of being redox sensitive.

Authors:  Patrícia A Madureira; David M Waisman
Journal:  Int J Mol Sci       Date:  2013-02-07       Impact factor: 5.923

6.  Annexin A2 is a novel cellular redox regulatory protein involved in tumorigenesis.

Authors:  Patricia Alexandra Madureira; Richard Hill; Victoria Ann Miller; Carman Giacomantonio; Patrick Wing Kwong Lee; David Morton Waisman
Journal:  Oncotarget       Date:  2011-12

7.  Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.

Authors:  Gillian E Stillfried; Darren N Saunders; Marie Ranson
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 8.  New Insight on the Role of Plasminogen Receptor in Cancer Progression.

Authors:  Seema Kumari; Ramarao Malla
Journal:  Cancer Growth Metastasis       Date:  2015-07-29

9.  Genotoxic agents promote the nuclear accumulation of annexin A2: role of annexin A2 in mitigating DNA damage.

Authors:  Patricia A Madureira; Richard Hill; Patrick W K Lee; David M Waisman
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 10.  Annexin A2: its molecular regulation and cellular expression in cancer development.

Authors:  Chi-Yun Wang; Chiou-Feng Lin
Journal:  Dis Markers       Date:  2014-01-23       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.